Jiangsu wuzhong(SH:600200)2017-04-27 16:00Financial Performance - Operating revenue for the period reached CNY 997,701,142.08, representing a significant increase of 77.70% year-on-year[6] - Net profit attributable to shareholders was CNY 25,211,130.41, a turnaround from a loss of CNY 9,497,635.50 in the same period last year[6] - Basic and diluted earnings per share improved to CNY 0.035, compared to a loss of CNY 0.014 in the previous year[6] - The total profit for the period was RMB 3,074.96 million, a significant increase from RMB 69.98 million in the previous period, indicating strong performance across the company's main business segments[14] - Net profit attributable to the parent company was RMB 2,521.11 million, a recovery from a loss of RMB 949.76 million in the same period last year[14] - The net profit for Q1 2017 was CNY 25,922,252.24, a significant recovery from a net loss of CNY 2,094,947.46 in the same period last year[30] - The total profit for Q1 2017 reached CNY 30,749,631.55, compared to CNY 699,791.55 in Q1 2016, indicating a strong turnaround[30] Cash Flow - The net cash flow from operating activities was negative CNY 40,589,931.46, a decline of 130.98% compared to the previous year[6] - The net cash flow from operating activities was negative at RMB -4,058.99 million, a decline of 130.98% compared to RMB 13,103.16 million in the previous period, mainly due to increased payments for raw materials[14] - The total cash inflow from operating activities was 87,680,628.91 RMB, down 61.3% from 226,348,384.45 RMB in the previous period[41] - The cash flow from investment activities showed a net outflow of -2,160,421.66 RMB, compared to -13,736,408.53 RMB in the previous period, indicating an improvement[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,165,988,721.16, a decrease of 1.40% compared to the end of the previous year[6] - Non-current assets totaled ¥2,518,247,727.56 as of March 31, 2017, compared to ¥2,501,779,402.01 at the beginning of the year, indicating a slight increase of 0.7%[26] - Total liabilities were reported at ¥581,744,268.44, down from ¥640,511,627.29, showing a decline of 9.2%[27] - Current liabilities decreased to ¥372,974,203.81 from ¥436,543,319.52, a reduction of 14.6%[26] Shareholder Information - The total number of shareholders at the end of the reporting period was 76,491[10] - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., held 17.01% of the shares, with 122,795,762 shares pledged[11] Government Support and Non-Recurring Items - The company received government subsidies totaling CNY 5,973,632.34 related to new drug research and development[9] - The company reported a total of CNY 5,670,273.34 in non-recurring gains and losses for the period[9] Investment and Development Activities - The company has completed the Phase III clinical trial of its new anti-cancer drug, with plans to submit registration materials to the CFDA for commercialization[15] - The company has acquired a land parcel of 39,183 square meters for commercial and residential use at a total price of RMB 67,590,675, with a planned construction project underway[17] - The company has made payments totaling RMB 4,477.15 million for land and fees related to the construction of its third-phase project at Xiangshui Henglida[18] - The company is actively pursuing the registration and marketing of its new drug project, aiming for rapid industrialization and academic promotion[15] Cost Management - Operating costs increased to RMB 87,181.41 million, reflecting an 81.69% rise from RMB 47,984.01 million, driven by the growth in operating revenue[14] - The company incurred management expenses of CNY 12,376,313.02, down from CNY 17,373,498.61 in the previous year, reflecting cost control efforts[33] - The financial expenses decreased to CNY 1,651,731.61 from CNY 2,058,732.06, indicating improved financial management[33]